To amend the notification provision with respect to drugs deemed to have risk evaluation and mitigation strategies.
What it does: Inserts “, except with respect to the drug Mifeprex (mifepristone), such assessment shall be submi…” before the period at the end
Sen. Jim DeMint (R-SC)Inserts “, except with respect to the drug Mifeprex (mifepristone), such assessment shall be submi…” before the period at the end
InsertsSection 214(b)(3)(B)Inserted: , except with respect to the drug Mifeprex (mifepristone), such assessment shall be submitted 6 months after the applicant is so notified
Original wording
In section 214(b)(3)(B) of the bill, insert “, except with respect to the drug Mifeprex (mifepristone), such assessment shall be submitted 6 months after the applicant is so notified” before the period at the end.
Read automatically from the Congressional Record. Check the original before relying on it.
As printed
In section 214(b)(3)(B) of the bill, insert “, except with respect to the drug Mifeprex (mifepristone), such assessment shall be submitted 6 months after the applicant is so notified” before the period at the end.
Legislative Activity
Stay on top of the latest movement without scrolling through every action
Senate amendment submitted
May 2, 2007
View full timeline
Senate amendment submitted
May 2, 2007
Senate amendment proposed (on the floor): Amendment SA 1018 proposed by Senator DeMint.(consideration: CR S5469-5470, S5471-5472; text: CR S5469)
May 2, 2007
Senate amendment agreed to: Amendment SA 1018 agreed to in Senate by Unanimous Consent.
May 2, 2007
Amendment SA 1018 proposed by Senator DeMint. (consideration: CR S5469-5470, S5471-5472; text: CR S5469) To amend the notification provision with respect to drugs deemed to have risk evaluation and mitigation strategies.
May 2, 2007
Amendment SA 1018 agreed to in Senate by Unanimous Consent.
May 2, 2007